Rocket Pharmaceuticals (RCKT) investor relations material

Company overview and strategy

• Focuses on genetic cardiomyopathies, including Danon disease, PKP2 arrhythmogenic cardiomyopathy, and BAG3 dilated cardiomyopathy, with a cardiac-centric pipeline.

• Achieved first FDA approval for LAD-I with Kresladi, supporting a cash runway into Q2 2028.

• Transitioning legacy ex vivo lentiviral programs to potential partners while prioritizing cardiovascular genetic medicines.

• In-house AAV manufacturing facility enables process control, cost efficiency, and regulatory agility.

• Building commercialization infrastructure to support future product launches and payer access.

Clinical program updates and milestones

• Danon pivotal trial resumed after resolving a partial clinical hold; recalibrated dosing and safety protocols implemented.

• Phase I Danon data showed 100% success on key endpoints, supporting confidence in phase II.

• PKP2 phase I demonstrated protein expression and clinical improvements; pivotal trial discussions ongoing with FDA.

• BAG3 phase I to begin soon, with endpoints leveraging established measures for dilated cardiomyopathy.

• Comprehensive program updates, including epidemiology and trial status, expected in the second half of the year.

Regulatory and industry landscape

• Maintains collaborative, iterative dialogue with FDA, leveraging recent guidance and strong agency relationships.

• Industry-wide focus on execution, manufacturing, and regulatory engagement as gene therapy matures.

• FDA requires a three-patient safety run for Danon before broader pivotal enrollment; trial design flexibility remains.

• Anticipates different regulatory pathways for PKP2 and BAG3 compared to Danon due to disease characteristics.

• Written communications and thorough trial design are prioritized to align with regulatory expectations.